Posts by Sandra Ansanay-Alex
Limula Enters Commercial Phase of Its Cell Therapy Platform
Vaud-Based biotech company Limula is transitioning from a technology-driven startup to a commercial entity preparing for industrial production and market deployment of LimONE, its cell therapy manufacturing platform. After several years of development, Limula has successfully moved from vision to revenue. In early 2026, Limula engaged with eight biotech companies and clinical centers, generating its…
Read MoreViktor Award 2025: Celebrating Bold Innovation in Swiss Healthcare
The Viktor Award 2025, often referred to as the “Oscar of Swiss Healthcare,” returns for its fifth edition, honoring individuals and institutions that have made a significant impact on Switzerland’s health sector. Nominees are HUG’s project GESICA, Swiss Personalised Health Network, Pink Cube , ART-THERAPY Foundation and the Swiss Cancer Institute. This year, several groundbreaking…
Read MoreDSM-Firmenich Divests its Animal Nutrition and Health business
The Dutch-Swiss group DSM-Firmenich announced that it will sell its animal nutrition and health business to the investment fund CVC Capital Partners based on an enterprise value of €2.2 billion. A move that marks the completion of the group’s strategic transformation towards the nutrition, health, and beauty markets for human use. With this sale, the…
Read MoreFood and Biotechnology Conference
The Food and Biotechnology Conference is taking place on 8-9 September 2026 in HES-SO Valais Wallis – Sion Organized by the Plant, Agriculture and Food Division of the European Federation of Biotechnology, this two-day event will bring together leading researchers, innovators, and industry professionals to explore the latest advances, trends, and breakthroughs in the field. Don’t miss this…
Read MoreSwissmedic approves donanemab for the treatment of early-stage Alzheimer’s disease
The drug, developed by Eli Lilly, slows the progression of the disease, but cannot stop or cure it. Alzheimer Switzerland and Swiss Memory Clinics welcome this decision, but emphasize that many people with Alzheimer’s disease and their families still face significant challenges. On February 4, 2026, the Swiss Agency for Therapeutic Products (Swissmedic) approved the…
Read MoreNoa Schmid gets the CSEM Inventor Award 2026
Micromechanical engineer Noa Schmid has been awarded the CSEM Inventor Award 2026 in recognition of his foundational contributions to precision liquid-handling technologies—key components of modern laboratory automation, diagnostics, and health monitoring. Over more than two decades at CSEM, Noa Schmid has played a central role in advancing devices capable of controlling and dispensing liquids at…
Read MoreGeorge Coukos appointed director of new Ludwig Laboratory for Cell Therapy in New York
The Ludwig Institute for Cancer Research has established the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine’s Sandra and Edward Meyer Cancer Center. The laboratory is directed by former Head of CHUV Oncology Department and Ludwig Lausanne Director George Coukos, a physician-scientist and global authority on tumor immunology and cellular immunotherapy. George Coukos returns…
Read MoreSwiss Biotech HemostOD Secures CHF 2 Million Innosuisse Grant to Advance Universal Platelet Technology
Swiss Health Valley biotech company HemostOD has been awarded a CHF 2 million competitive grant from Innosuisse, the Swiss Innovation Agency, to support key development milestones for its groundbreaking platelet manufacturing platform. The non-dilutive funding will play a pivotal role in strengthening HemostOD’s financial position as it moves towards major value-inflection points, including progressing toward…
Read MoreGivaudan Invests USD 110 Million in New Fragrance Facility in Mexico
Givaudan has announced a strategic investment of USD 110 million to build a new fragrance compounding facility in Pedro Escobedo, Mexico, reinforcing its presence in Latin America and supporting its long-term growth ambitions under the company’s 2030 strategy. The new site will operate under Givaudan’s “in the region, for the region” supply model, bringing production…
Read MoreTech4Eva Concludes After Five Years of Advancing Women’s Health Innovation
After five years of fostering innovation in women’s health, the Tech4Eva programme—co-founded by EPFL Innovation Park and Groupe Mutuel—will officially come to an end in 2026. Launched as a pioneering Femtech accelerator, Tech4Eva has grown into an internationally recognized exchange platform connecting entrepreneurs, researchers, corporates, and healthcare professionals with a shared mission: improving women’s health…
Read More